Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.

Abstract

Unlike the results obtained with prior HCV regimens, this study suggests that similar SVR rates are achieved with LDV/SOF in clinical trial-based studies and real-world studies. Further, achieving an SVR in real-world clinical practice was not associated with excess costs.